Forbion Capital Fund IV Cooperatief U.A. → NewAmsterdam Pharma Co N.V. NAMSW

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 14/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline
Held by 2 tracked 13F institutional managers

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

42 shares short · 0.0% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

2 holders · $142.56M

Duquesne Family OfficeViking Global

Other 13D/G Filings on NewAmsterdam Pharma Co N.V.

Filed	Form	Filer	Stake	Shares
2026-09-22	SCHEDULE 13D/A	Frazier Life Sciences X, L.P.	8.70%	7,329,857	view →
2026-05-14	SCHEDULE 13D/A	BCLS II Investco, LP	—	2,059,896	view →
2025-11-07	SCHEDULE	BCLS II Investco, LP	9.99%	11,422,504	view →
2025-09-30	SCHEDULE	Forbion Capital Fund IV Cooperatief U.A.	8.30%	9,316,914	view →
2023-06-13	SC	BCLS II Investco, LP	—	—	view →

Other Filings by Forbion Capital Fund IV Cooperatief U.A.

Filed	Form	Issuer	Stake	Shares
2025-09-30	SCHEDULE	NewAmsterdam Pharma Co N.V. NAMSW	8.30%	9,316,914	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →